LAWSUITS NEWS & LEGAL INFORMATION
FDA Warns of Increased Risk of Invokana Leg and Foot Amputations
Washington, DC: The US Food and Drug Administration (FDA) is alerting the public about interim safety results from an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with the diabetes medicine canagliflozin (Invokana, Invokamet).
The agency has not determined whether canagliflozin increases the risk of leg and foot amputations, but are currently investigating this new safety issue.
Canagliflozin is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Canagliflozin lowers blood sugar by causing the kidneys to remove sugar from the body through the urine. It is available as a single-ingredient product under the brand name Invokana and also in combination with the diabetes medicine metformin under the brand name Invokamet.
In the ongoing Canagliflozin Cardiovascular Assessment Study (CANVAS) clinical trial, the trial' independent data monitoring committee (IDMC) identified an increased risk of leg and foot amputations.
The amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment. An interim analysis showed that over a year' time, the risks of amputation for patients in the trial were equivalent to:
7 out of every 1,000 patients treated with 100 mg daily of canagliflozin
5 out of every 1,000 patients treated with 300 mg daily of canagliflozin
3 out of every 1,000 patients treated with placebo
Patients in the CANVAS trial have been followed for an average of 4.5 years to date. The IDMC has recommended, based on an overall assessment, that the CANVAS trial continue.
The IDMC has also reported that a second, similar trial evaluating canagliflozin, the CANVAS-R trial, has not shown the same risks of increased leg and foot amputations to date. Patients in the CANVAS-R trial have been followed for an average of 9 months.
Last updated on
The agency has not determined whether canagliflozin increases the risk of leg and foot amputations, but are currently investigating this new safety issue.
Canagliflozin is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Canagliflozin lowers blood sugar by causing the kidneys to remove sugar from the body through the urine. It is available as a single-ingredient product under the brand name Invokana and also in combination with the diabetes medicine metformin under the brand name Invokamet.
In the ongoing Canagliflozin Cardiovascular Assessment Study (CANVAS) clinical trial, the trial' independent data monitoring committee (IDMC) identified an increased risk of leg and foot amputations.
The amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment. An interim analysis showed that over a year' time, the risks of amputation for patients in the trial were equivalent to:
7 out of every 1,000 patients treated with 100 mg daily of canagliflozin
5 out of every 1,000 patients treated with 300 mg daily of canagliflozin
3 out of every 1,000 patients treated with placebo
Patients in the CANVAS trial have been followed for an average of 4.5 years to date. The IDMC has recommended, based on an overall assessment, that the CANVAS trial continue.
The IDMC has also reported that a second, similar trial evaluating canagliflozin, the CANVAS-R trial, has not shown the same risks of increased leg and foot amputations to date. Patients in the CANVAS-R trial have been followed for an average of 9 months.
Legal Help
If you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.Last updated on
INVOKANA LEG AND FOOT AMPUTATIONS LEGAL ARTICLES AND INTERVIEWS
Plaintiff Blames Loss of his Lower Leg to Invokana Use
Invokana Amputation Lawsuits Cite Consumer Advertising
New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk
March 21, 2018
Trenton, NJ: While a plaintiff having filed a recent Invokana lawsuit makes assertions pertaining to Invokana linked with cardiovascular injuries and kidney failure, it was the amputation of his right leg below the knee less than a year after starting on Invokana that ultimately prompted the plaintiff to move forward with his Invokana side effects lawsuit. READ MORE
Invokana Amputation Lawsuits Cite Consumer Advertising
December 22, 2017
Trenton, NJ: The pleasant-looking man looks into the camera and tells us that taking Invokana “may also help you lose a little weight.” Big problem. The FDA has not approved Invokana for weight-loss. The drug has had a rocky history since its approval in 2013, and a recent FDA warning cites the danger of Invokana leg and foot amputations. Direct-to-consumer drug advertising can magnify the harm that dangerous drugs do to patients who may spend more time listening to that friendly man (or his commercial kin) than they do talking with their own doctors. READ MORE
New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk
October 2, 2017
Washington, DC: Despite exhaustive studies that found an increased risk of amputation among Invokana diabetes patients, Janssen Pharmaceuticals has published its own version of research. READ MORE
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News